{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:23Z","timestamp":1786980143635,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T00:00:00Z","timestamp":1334793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00417-012-2022-8","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T23:44:27Z","timestamp":1334706267000},"page":"1-7","source":"Crossref","is-referenced-by-count":57,"title":["Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization"],"prefix":"10.1007","volume":"251","author":[{"given":"Akio","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Ooto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagahisa","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,19]]},"reference":[{"key":"2022_CR1","first-page":"2103","volume":"41","author":"DO Mutti","year":"2000","unstructured":"Mutti DO, Zadnik K (2000) Age-related decreases in the prevalence of myopia: longitudinal change or cohort effect? Invest Ophthalmol Vis Sci 41:2103\u20132107","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2022_CR2","first-page":"2566","volume":"43","author":"KE Lee","year":"2002","unstructured":"Lee KE, Klein BE, Klein R, Wong TY (2002) Changes in refraction over 10\u00a0years in an adult population: the Beaver Dam Eye study. Invest Ophthalmol Vis Sci 43:2566\u20132571","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2022_CR3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archopht.1963.00960040172007","volume":"6","author":"BJ Curtin","year":"1963","unstructured":"Curtin BJ (1963) The pathogenesis of congenital myopia. A study of 66 cases. Arch Ophthalmol 6:166\u2013173","journal-title":"Arch Ophthalmol"},{"key":"2022_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9394(81)90170-7","volume":"91","author":"ML Hotchkiss","year":"1981","unstructured":"Hotchkiss ML, Fine SL (1981) Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 91:177\u2013183","journal-title":"Am J Ophthalmol"},{"key":"2022_CR5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0161-6420(99)90484-0","volume":"106","author":"H Tabandeh","year":"1999","unstructured":"Tabandeh H, Flynn HWJ, Scott IU, Lewis ML, Rosenfeld PJ, Rodriguez F, Rodriguez A, Singerman LJ, Schiffman J (1999) Visual acuity outcomes of patients 50\u00a0years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 106:2063\u20132067","journal-title":"Ophthalmology"},{"key":"2022_CR6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","volume":"110","author":"T Yoshida","year":"2003","unstructured":"Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110:1297\u20131305","journal-title":"Ophthalmology"},{"key":"2022_CR7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/bjo.2005.074716","volume":"89","author":"WM Chan","year":"2005","unstructured":"Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS (2005) Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 89:1522\u20131528","journal-title":"Br J Ophthalmol"},{"key":"2022_CR8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/bjo.87.7.856","volume":"87","author":"JM Ruiz-Moreno","year":"2003","unstructured":"Ruiz-Moreno JM, Montero JA (2003) Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 87:856\u2013859","journal-title":"Br J Ophthalmol"},{"key":"2022_CR9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.icu.0000120709.35941.e9","volume":"15","author":"K Ohno-Matsui","year":"2004","unstructured":"Ohno-Matsui K, Yoshida T (2004) Myopic choroidal neovascularization: natural course and treatment. Curr Opin Ophthalmol 15:197\u2013202","journal-title":"Curr Opin Ophthalmol"},{"key":"2022_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ajo.2010.06.046","volume":"151","author":"K Hayashi","year":"2011","unstructured":"Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Hayashi W, Wang J, Yoshida T, Tokoro T, Mochizuki M (2011) Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol 151:137\u2013147","journal-title":"Am J Ophthalmol"},{"key":"2022_CR11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","volume":"110","author":"KJ Blinder","year":"2003","unstructured":"Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3. Ophthalmology 110:667\u2013673","journal-title":"Ophthalmology"},{"key":"2022_CR12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","volume":"147","author":"M Gharbiya","year":"2009","unstructured":"Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147:84\u201393","journal-title":"Am J Ophthalmol"},{"key":"2022_CR13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00417-009-1117-3","volume":"247","author":"L Konstantinidis","year":"2009","unstructured":"Konstantinidis L, Mantel I, Zografos L, Ambresin A (2009) Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch Clin Exp Ophthalmol 247:1567\u20131569","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2022_CR14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IAE.0b013e3181c9691e","volume":"30","author":"RM Silva","year":"2010","unstructured":"Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN (2010) Intravitreal ranibizumab for myopic choroidal neovascularization 12-month results. Retina 30:407\u2013412","journal-title":"Retina"},{"key":"2022_CR15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/eye.2009.88","volume":"23","author":"JM Mones","year":"2009","unstructured":"Mones JM, Amselem L, Serrano A, Garcia M, Hijano M (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 23:1275\u20131280","journal-title":"Eye"},{"key":"2022_CR16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IAE.0b013e31819ed6bd","volume":"29","author":"TY Lai","year":"2009","unstructured":"Lai TY, Chan WM, Liu DT, Lam DS (2009) Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 29:750\u2013756","journal-title":"Retina"},{"key":"2022_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/IAE.0b013e3181bcef24","volume":"30","author":"F Lalloum","year":"2010","unstructured":"Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N (2010) Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30:399\u2013406","journal-title":"Retina"},{"key":"2022_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajo.2010.09.021","volume":"151","author":"C Calvo-Gonzalez","year":"2011","unstructured":"Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J (2011) Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 151:529\u2013534","journal-title":"Am J Ophthalmol"},{"key":"2022_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000317908","volume":"225","author":"FM Falcao-Reis","year":"2011","unstructured":"Falcao-Reis FM, Carneiro AM, Silva RM, Veludo MJ, Barbosa A, Ruiz-Moreno JM, Falcao MS, Brandao EM (2011) Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica 225:81\u201388","journal-title":"Ophthalmologica"},{"key":"2022_CR20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/IAE.0b013e31821800a4","volume":"31","author":"P Iacono","year":"2011","unstructured":"Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F (2011) Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina 31:1841\u20131847","journal-title":"Retina"},{"key":"2022_CR21","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/IAE.0b013e3181e22659","volume":"30","author":"JM Ruiz-Moreno","year":"2010","unstructured":"Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Pinero DP (2010) Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 30:1609\u20131615","journal-title":"Retina"},{"key":"2022_CR22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2011.0023","volume":"27","author":"CH Chen","year":"2011","unstructured":"Chen CH, Wu PC, Chen YJ, Liu YC, Kuo HK (2011) Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. J Ocul Pharmacol Ther 27:395\u2013400","journal-title":"J Ocul Pharmacol Ther"},{"key":"2022_CR23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/bjo.2009.174243","volume":"95","author":"M Vadala","year":"2011","unstructured":"Vadala M, Pece A, Cipolla S, Monteleone C, Fasolino G, Casuccio A, Cillino S (2011) Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 95:657\u2013661","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2022_CR24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","volume":"32","author":"K Hayashi","year":"2012","unstructured":"Hayashi K, Shimada N, Moriyama M, Hayashi W, Tokoro T, Ohno-Matsui K (2012) Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 32(4):687\u2013695. doi: 10.1097\/IAE.0b013e3182278bae","journal-title":"Retina"},{"key":"2022_CR25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","volume":"147","author":"Y Ikuno","year":"2009","unstructured":"Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147:94\u2013100","journal-title":"Am J Ophthalmol"},{"key":"2022_CR26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","volume":"148","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M (2009) Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 148:396\u2013408","journal-title":"Am J Ophthalmol"},{"key":"2022_CR27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2009.166025","volume":"94","author":"T Baba","year":"2010","unstructured":"Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864\u2013870","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"2022_CR28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00417-011-1654-4","volume":"249","author":"L El Matri","year":"2011","unstructured":"El Matri L, Kort F, Chebil A, Bouraoui R, Merdassi A, Bouladi M (2011) Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population. Graefes Arch Clin Exp Ophthalmol 249(9):1287\u20131293. doi: 10.1007\/s00417-011-1654-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2022_CR29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","volume":"149","author":"Y Ikuno","year":"2010","unstructured":"Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2010) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149:140\u2013146","journal-title":"Am J Ophthalmol"},{"key":"2022_CR30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00417-009-1285-1","volume":"248","author":"B Voykov","year":"2010","unstructured":"Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F (2010) Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2\u00a0years? Graefes Arch Clin Exp Ophthalmol 248:543\u2013550","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2022_CR31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-010-1340-y","volume":"248","author":"JM Ruiz-Moreno","year":"2010","unstructured":"Ruiz-Moreno JM, Montero JA (2010) Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 248:937\u2013941","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2022_CR32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000333213","volume":"227","author":"N Franqueira","year":"2012","unstructured":"Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J, Silva R (2012) Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 227(1):39\u201344. doi: 10.1159\/000333213","journal-title":"Ophthalmologica"},{"key":"2022_CR33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/IAE.0b013e3181bd2d51","volume":"30","author":"K Yamashiro","year":"2010","unstructured":"Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H, Ooto S, Sasahara M, Iwama D, Yoshimura N (2010) Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 30:485\u2013490","journal-title":"Retina"},{"key":"2022_CR34","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/bjo.2007.132795","volume":"92","author":"JM Ruiz-Moreno","year":"2008","unstructured":"Ruiz-Moreno JM, Amat P, Montero JA, Lugo F (2008) Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4\u00a0years' outcome. Br J Ophthalmol 92:792\u2013794","journal-title":"Br J Ophthalmol"},{"key":"2022_CR35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","volume":"243","author":"K Hayashi","year":"2005","unstructured":"Hayashi K, Ohno-Matsui K, Yoshida T, Kobayashi K, Kojima A, Shimada N, Yasuzumi K, Futagami S, Tokoro T, Mochizuki M (2005) Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 243:13\u201319","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2022_CR36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00417-003-0803-9","volume":"242","author":"A Kojima","year":"2004","unstructured":"Kojima A, Ohno-Matsui K, Teramukai S, Yoshida T, Ishihara Y, Kobayashi K, Shimada N, Yasuzumi K, Futagami S, Tokoro T, Mochizuki M (2004) Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 242:114\u2013119","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2022_CR37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajo.2004.05.074","volume":"138","author":"R Axer-Siegel","year":"2004","unstructured":"Axer-Siegel R, Ehrlich R, Weinberger D, Rosenblatt I, Shani L, Yassur Y, Priel E, Kramer M (2004) Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 138:602\u2013607","journal-title":"Am J Ophthalmol"},{"key":"2022_CR38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bjo.87.2.173","volume":"87","author":"JA Montero","year":"2003","unstructured":"Montero JA, Ruiz-Moreno JM (2003) Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87:173\u2013176","journal-title":"Br J Ophthalmol"},{"key":"2022_CR39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/eye.2010.226","volume":"25","author":"H Nakanishi","year":"2011","unstructured":"Nakanishi H, Tsujikawa A, Yodoi Y, Ojima Y, Otani A, Tamura H, Yamashiro K, Ooto S, Yoshimura N (2011) Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye 25:375\u2013381","journal-title":"Eye"},{"key":"2022_CR40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.survophthal.2007.12.004","volume":"53","author":"G Soubrane","year":"2008","unstructured":"Soubrane G (2008) Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 53:121\u2013138","journal-title":"Surv Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-012-2022-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-012-2022-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-012-2022-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:48:17Z","timestamp":1559058497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-012-2022-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s00417-012-2022-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}